";s:4:"text";s:5147:" BVYC0236 05/20By following this link, you are now leaving BIKTARVY.com. bilirubin increases were observed in 12% of subjects administered BIKTARVY
h���A 0ð40�}\Gcw��������z�C
expressing HIV-1 isolates with reduced susceptibility to FTC were
of lactating monkeys following a single subcutaneous (30 mg/kg) dose of
MATE1. (50 mg + 200 mg/25 mg) (N=325) once daily.In Trial 1489, the mean age was 34 years (range 18–71),
approximately 60 times higher than human exposures at the RHD.Tenofovir alafenamide: TAF was administered orally to
drugs.BIC inhibits the strand
PBMCs, primary monocyte/macrophage cells and CD4-T lymphocytes. These are not all the possible side effects of BIKTARVY. than those listed in a Patient Information leaflet. births was 2.3% (95% CI: 1.7% to 3.0%) with first trimester exposure to
immediately of any symptoms of infection, as in some patients with advanced HIV
If appropriate, anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since post-treatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.The concomitant use of BIKTARVY with certain other drugs may result in known or potentially significant drug interactions, some of which may lead to Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy. If you need support affording your medicine, we may be able to help. DRV (given with either cobicistat or ritonavir).Treatment outcomes of Trials 1844 and 1878 through Week
instruct mothers not to breastfeed if they are receiving BIKTARVY.Bictegravir: BIC was detected in the plasma of nursing
[and lactation day 20] at tenofovir exposures of approximately 12 [19] times
2.4±0.4 nM, and the protein-adjusted EC95 value was 361 nM (0.162 micrograms
See full prescribing information for complete boxed warning.Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY.
mouse study at doses of up to 100 mg/kg/day in males and 300 mg/kg/day in
the plasma concentrations of BIC.TAF is a substrate of P-glycoprotein (P-gp) and breast
rash, and depression.Suicidal ideation, suicide
drug and may not reflect the rates observed in practice.The primary safety assessment of BIKTARVY was based on
Precautions while using Biktarvy It is very important that your doctor check your or your child's progress at regular visits , especially during the first few weeks that you take this medicine. cancer resistance protein (BCRP). substitutions and 44 with 2 or more substitutions). nursing rat pups likely due to the presence of BIC in milk, and tenofovir has
greater than (rats and mice) those in humans at the recommended human dose
3 trials of BIKTARVY showed that age did not have a clinically relevant effect
30 nM) and against HIV-2 was 7 nM.The antiviral activity of TAF against laboratory and
FTC-containing regimens and 2.0% (95% CI: 1.3% to 3.1%) with the second/third
Tenofovir diphosphate is
phosphorus. Subjects were randomized in a 1:1 ratio to
norgestimate, sertraline, sofosbuvir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir.Patients with HIV-1 should be tested for the presence of
FTC was not genotoxic in the reverse mutation bacterial test (Ames test), mouse lymphoma or mouse micronucleus assays.FTC did not affect fertility in male rats at approximately 140 times or in male and female mice at approximately 60 times higher exposures (AUC) than in humans given the recommended dose of BIKTARVY. 0000033049 00000 n
antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA
Consider the potential for drug interactions prior to and during BIKTARVY
reported in patients who are coinfected with HBV and HIV-1 and have
Recipient's Email. higher than the exposure in humans at the recommended daily dose of BIKTARVY. 0000021661 00000 n
metabolite tenofovir diphosphate. other renally eliminated drugs and this may increase the risk of adverse
(cohort 1), and in virologically-suppressed subjects between the ages of 6 to
for use in patients with severe hepatic impairment [see No data are available on overdose of BIKTARVY in
For more information, call 1-800-445-3235 or
trials summarized in Table 11.In Trial 1489, subjects were
How should I store BIKTARVY? FTC, and TAF was not antagonistic with respect to antiviral activity in cell
hepatic transporters OATP1B1, OATP1B3, OCT1, BSEP, renal transporters OAT1,
No dosage adjustment of BIKTARVY is recommended in
should be limited.Clinically relevant changes in
The mean